Pipeline Overview

G1 is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. Our drug candidates were designed to be administered in combination with many conventional and emerging cancer therapeutics.

We own world-wide commercial rights to trilaciclib (G1T28), G1T38, and G1T48 and have more than 115 U.S. and international patents and pending patent applications covering our product development programs.